Familial chylomicronaemia syndrome (FCS)

Active Ingredient: Plozasiran

Indication for Plozasiran

Population group: only adults (18 years old or older)
Therapeutic intent: Adjunct intent

Plozasiran is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS).

For this indication, competent medicine agencies globally authorize below treatments:

25 mg once every 3 months

For:

Dosage regimens

Subcutaneous, 25 milligrams plozasiran, once every 3 months.

Detailed description

Patient selection

When considering the use of plozasiran, it is important that FCS diagnosis of a patient is established by either genetic testing, or by the presence of the following clinical criteria: fasting triglyceride (TG) levels ≥10 mmol/L (≥880 mg/dL) that are refractory to standard lipid-lowering therapy and at least one of the following: prior history of acute pancreatitis not caused by alcohol or cholelithiasis, history of recurrent hospitalisations for severe abdominal pain without other explainable cause, history of childhood pancreatitis, or family history of hypertriglyceridaemia-induced pancreatitis.

Posology

The recommended dose of plozasiran is 25 mg administered as a single subcutaneous injection every 3 months.

Missed dose

If a dose is missed, plozasiran should be administered as soon as possible. Thereafter, dosing should be resumed every 3 months from the most recently administered dose.

Elderly

No dose adjustment is required for elderly patients ≥65 years of age.

Dosage considerations

The first injection administered by the patient or caregiver should be performed under the guidance of an appropriately qualified healthcare professional. Sites for injection include the upper arm (when administered by a caregiver), thigh, and abdomen (except for a 5 cm area around the navel). Plozasiran should not be injected into an area where the skin is tender, bruised, red, hard, or cut, or with scars or stretch marks. Plozasiran should not be injected in the same area where other medicines are injected.

Active ingredient

Plozasiran

Plozasiran is a small interfering RNA (siRNA, double-stranded oligonucleotide) conjugated with N-acetylgalactosamine to facilitate delivery to and uptake by hepatocytes. In hepatocytes, plozasiran selectively degrades the mRNA for apolipoprotein C3 (APOC3) through the RNA interference mechanism resulting in reduced levels of hepatic and serum APOC3 protein. This, in turn, enhances the activity of lipoprotein lipase and hepatocyte uptake of TG-rich lipoprotein remnants leading to decreases in serum TG.

Read more about Plozasiran

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.